{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T19:00:13Z","timestamp":1761850813354,"version":"build-2065373602"},"reference-count":49,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T00:00:00Z","timestamp":1790380800000},"content-version":"am","delay-in-days":360,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01DA046532"],"award-info":[{"award-number":["R01DA046532"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.jpet.2025.103691","type":"journal-article","created":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T00:25:41Z","timestamp":1756945541000},"page":"103691","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Interactions between fentanyl and 2,5-dimethoxy-4-methylamphetamine: Ventilatory effects in nonhuman primates"],"prefix":"10.1016","volume":"392","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0958-5397","authenticated-orcid":false,"given":"David R.","family":"Maguire","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.jpet.2025.103691_bib1","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1176\/appi.ajp.20230172","article-title":"Psychedelics as transformative therapeutics","volume":"180","author":"Roth","year":"2023","journal-title":"Am J Psychiatry"},{"issue":"10","key":"10.1016\/j.jpet.2025.103691_bib2","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1001\/jamapsychiatry.2023.1968","article-title":"Psychedelics as therapeutics-potential and challenges","volume":"80","author":"Volkow","year":"2023","journal-title":"JAMA Psychiatry"},{"issue":"4","key":"10.1016\/j.jpet.2025.103691_bib3","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1080\/02791072.2023.2251133","article-title":"Beyond psilocybin: reviewing the therapeutic potential of other serotonergic psychedelics in mental and substance use disorders","volume":"56","author":"Wong","year":"2024","journal-title":"J Psychoactive Drugs"},{"key":"10.1016\/j.jpet.2025.103691_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2023.106998","article-title":"IUPHAR-review: the integration of classic psychedelics into current substance use disorder treatment models","volume":"199","author":"Yaden","year":"2024","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.jpet.2025.103691_bib5","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2023.1183740","article-title":"Psychedelic therapy in the treatment of addiction: the past, present and future","volume":"14","author":"Zafar","year":"2023","journal-title":"Front Psychiatry"},{"issue":"5","key":"10.1016\/j.jpet.2025.103691_bib7","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1111\/add.16432","article-title":"Trends in hallucinogen-associated emergency department visits and hospitalizations in California, USA, from 2016 to 2022","volume":"119","author":"Garel","year":"2024","journal-title":"Addiction"},{"issue":"12","key":"10.1016\/j.jpet.2025.103691_bib8","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1111\/add.16259","article-title":"Hallucinogen use among young adults ages 19-30 in the United States: changes from 2018 to 2021","volume":"118","author":"Keyes","year":"2023","journal-title":"Addiction"},{"issue":"2","key":"10.1016\/j.jpet.2025.103691_bib9","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1080\/10826084.2023.2267105","article-title":"The rising use of LSD among business managers","volume":"59","author":"Korman","year":"2024","journal-title":"Subst Use Misuse"},{"issue":"4","key":"10.1016\/j.jpet.2025.103691_bib10","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1080\/02791072.2022.2142709","article-title":"An assessment of psychedelic knowledge among people using psychedelics naturalistically","volume":"55","author":"Kruger","year":"2023","journal-title":"J Psychoactive Drugs"},{"issue":"12","key":"10.1016\/j.jpet.2025.103691_bib11","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1111\/add.15987","article-title":"Adolescent and adult time trends in US hallucinogen use, 2002-19: any use, and use of ecstasy, LSD and PCP","volume":"117","author":"Livne","year":"2022","journal-title":"Addiction"},{"key":"10.1016\/j.jpet.2025.103691_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2024.111086","article-title":"National and regional trends in seizures of shrooms (psilocybin) in the United States, 2017-2022","volume":"258","author":"Palamar","year":"2024","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.jpet.2025.103691_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2024.116043","article-title":"The efficacy and safety of MDMA-assisted psychotherapy for treatment of posttraumatic stress disorder: a systematic review and meta-analysis from randomized controlled trials","volume":"339","author":"Yang","year":"2024","journal-title":"Psychiatry Res"},{"issue":"2","key":"10.1016\/j.jpet.2025.103691_bib14","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1124\/pr.115.011478","article-title":"Psychedelics","volume":"68","author":"Nichols","year":"2016","journal-title":"Pharmacol Rev"},{"issue":"3801","key":"10.1016\/j.jpet.2025.103691_bib15","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1126\/science.158.3801.669","article-title":"2,5-dimethoxy-4-methyl-amphetamine (STP): a new hallucinogenic drug","volume":"158","author":"Snyder","year":"1967","journal-title":"Science"},{"year":"1991","series-title":"PIHKAL: A Chemical Love Story","author":"Shulgin","key":"10.1016\/j.jpet.2025.103691_bib16"},{"key":"10.1016\/j.jpet.2025.103691_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2019.107933","article-title":"Correlation between the potency of hallucinogens in the mouse head-twitch response assay and their behavioral and subjective effects in other species","volume":"167","author":"Halberstadt","year":"2020","journal-title":"Neuropharmacology"},{"issue":"5","key":"10.1016\/j.jpet.2025.103691_bib18","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1038\/npp.2010.232","article-title":"Effects of direct- and indirect-acting serotonin receptor agonists on the antinociceptive and discriminative stimulus effects of morphine in rhesus monkeys","volume":"36","author":"Li","year":"2011","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.jpet.2025.103691_bib19","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s00213-012-2803-0","article-title":"Effects of 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane (DOM) and quipazine on heroin self-administration in rhesus monkeys","volume":"225","author":"Maguire","year":"2013","journal-title":"Psychopharmacology (Berl)"},{"issue":"1","key":"10.1016\/j.jpet.2025.103691_bib20","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1124\/jpet.122.001318","article-title":"Effects of 2,5-dimethoxy-4-methylamphetamine (DOM) and 2-piperazin-1-yl-quinoline (quipazine) on fentanyl versus food choice in rhesus monkeys","volume":"384","author":"Maguire","year":"2023","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jpet.2025.103691_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2024.110163","article-title":"The psychedelic drug DOI reduces heroin motivation by targeting 5-HT2A receptors in a heroin and alcohol co-use model","volume":"261","author":"Bonilla","year":"2024","journal-title":"Neuropharmacology"},{"issue":"7842","key":"10.1016\/j.jpet.2025.103691_bib22","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/s41586-020-3008-z","article-title":"A non-hallucinogenic psychedelic analogue with therapeutic potential","volume":"589","author":"Cameron","year":"2021","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.jpet.2025.103691_bib23","doi-asserted-by":"crossref","DOI":"10.1111\/adb.12926","article-title":"Effects of 5-HT2A receptor stimulation on economic demand for fentanyl after intermittent and continuous access self-administration in male rats","volume":"26","author":"Martin","year":"2021","journal-title":"Addict Biol"},{"key":"10.1016\/j.jpet.2025.103691_bib24","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1221719","article-title":"Hallucinogenic potential: a review of psychoplastogens for the treatment of opioid use disorder","volume":"14","author":"Hornick","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jpet.2025.103691_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1239159","article-title":"\u03bc-opioid receptor agonists and psychedelics: pharmacological opportunities and challenges","volume":"14","author":"Salinsky","year":"2023","journal-title":"Front Pharmacol"},{"issue":"12","key":"10.1016\/j.jpet.2025.103691_bib26","doi-asserted-by":"crossref","first-page":"3036","DOI":"10.1111\/bcp.16045","article-title":"From taboo to treatment: the emergence of psychedelics in the management of pain and opioid use disorder","volume":"90","author":"Weleff","year":"2024","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.jpet.2025.103691_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1152\/physrev.1995.75.1.1","article-title":"Central control of breathing in mammals: neuronal circuitry, membrane properties, and neurotransmitters","volume":"75","author":"Bianchi","year":"1995","journal-title":"Physiol Rev"},{"issue":"1\u20132","key":"10.1016\/j.jpet.2025.103691_bib28","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.resp.2010.08.017","article-title":"The role of serotonin in respiratory function and dysfunction","volume":"174","author":"Hilaire","year":"2010","journal-title":"Respir Physiol Neurobiol"},{"key":"10.1016\/j.jpet.2025.103691_bib29","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/B978-0-444-63274-6.00011-4","article-title":"Serotonin neurons and central respiratory chemoreception: where are we now?","volume":"209","author":"Teran","year":"2014","journal-title":"Prog Brain Res"},{"issue":"7","key":"10.1016\/j.jpet.2025.103691_bib30","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1111\/bph.15580","article-title":"Understanding and countering opioid-induced respiratory depression","volume":"180","author":"Bateman","year":"2023","journal-title":"Br J Pharmacol"},{"issue":"1\u20132","key":"10.1016\/j.jpet.2025.103691_bib31","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0006-8993(02)02690-2","article-title":"Postnatal changes in the respiratory response of the conscious rat to serotonin 2A\/2C receptor activation are reflected in the developmental pattern of fos expression in the brainstem","volume":"942","author":"Cayetanot","year":"2002","journal-title":"Brain Res"},{"issue":"5","key":"10.1016\/j.jpet.2025.103691_bib32","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1152\/jn.00088.2021","article-title":"Eupnea and gasping in vivo are facilitated by the activation of 5-HT2A receptors","volume":"125","author":"Cummings","year":"2021","journal-title":"J Neurophysiol"},{"issue":"3","key":"10.1016\/j.jpet.2025.103691_bib33","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s00424-009-0741-4","article-title":"Serotonergic mechanisms on breathing modulation in the rat locus coeruleus","volume":"459","author":"de Souza Moreno","year":"2010","journal-title":"Pflugers Arch"},{"issue":"Pt 3","key":"10.1016\/j.jpet.2025.103691_bib34","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1113\/jphysiol.1995.sp020907","article-title":"5-HT2 receptor-controlled modulation of medullary respiratory neurones in the cat","volume":"487","author":"Lalley","year":"1995","journal-title":"J Physiol"},{"issue":"12","key":"10.1016\/j.jpet.2025.103691_bib35","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1523\/JNEUROSCI.5271-08.2009","article-title":"Raph\u00e9 neurons stimulate respiratory circuit activity by multiple mechanisms via endogenously released serotonin and substance P","volume":"29","author":"Ptak","year":"2009","journal-title":"J Neurosci"},{"issue":"2","key":"10.1016\/j.jpet.2025.103691_bib36","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S0022-3565(25)11383-9","article-title":"Pharmacological characterization of 5-hydroxytryptamine-induced apnea in the rat","volume":"260","author":"Yoshioka","year":"1992","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"10.1016\/j.jpet.2025.103691_bib37","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1124\/jpet.107.133348","article-title":"Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterization","volume":"325","author":"Thomsen","year":"2008","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jpet.2025.103691_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.pbb.2023.173673","article-title":"Interactions between lorcaserin and opioids: ventilation and food-versus-drug choice","volume":"234","author":"Maguire","year":"2024","journal-title":"Pharmacol Biochem Behav"},{"issue":"12","key":"10.1016\/j.jpet.2025.103691_bib39","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1002\/dta.3667","article-title":"The origin of 2,5-dimethoxy-4-methylamphetamine (DOM, STP)","volume":"16","author":"Trout","year":"2024","journal-title":"Drug Test Anal"},{"issue":"2","key":"10.1016\/j.jpet.2025.103691_bib40","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1124\/jpet.107.130625","article-title":"Discriminative stimulus effects of 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane in rhesus monkeys","volume":"324","author":"Li","year":"2008","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"10.1016\/j.jpet.2025.103691_bib41","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1124\/jpet.108.145458","article-title":"Discriminative stimulus effects of 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane in rhesus monkeys: antagonism and apparent pA2 analyses","volume":"328","author":"Li","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"issue":"7","key":"10.1016\/j.jpet.2025.103691_bib42","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1097\/FBP.0000000000000787","article-title":"Evaluation of potential punishing effects of 2,5-dimethoxy-4-methylamphetamine (DOM) in rhesus monkeys responding under a choice procedure","volume":"35","author":"Maguire","year":"2024","journal-title":"Behav Pharmacol"},{"issue":"8","key":"10.1016\/j.jpet.2025.103691_bib43","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1007\/s00213-025-06751-9","article-title":"A humanized monoclonal antibody attenuates fentanyl self-administration and reverses and prevents fentanyl-induced ventilatory depression in rhesus monkeys","volume":"242","author":"Galbo-Thomma","year":"2025","journal-title":"Psychopharmacology (Berl)"},{"issue":"2","key":"10.1016\/j.jpet.2025.103691_bib44","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1007\/s002130050606","article-title":"Studies on benzodiazepines and opioids administered alone and in combination in rhesus monkeys: ventilation and drug discrimination","volume":"137","author":"Gerak","year":"1998","journal-title":"Psychopharmacology (Berl)"},{"issue":"12","key":"10.1016\/j.jpet.2025.103691_bib45","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1111\/bcp.16264","article-title":"Psychedelic research, assisted therapy and the role of the anaesthetist: a review and insights for experimental and clinical practices","volume":"90","author":"Lima","year":"2024","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.jpet.2025.103691_bib46","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.annemergmed.2024.06.025","article-title":"Clinical effects of psychedelic substances reported to United States poison centers: 2012 to 2022","volume":"84","author":"Simon","year":"2024","journal-title":"Ann Emerg Med"},{"issue":"2","key":"10.1016\/j.jpet.2025.103691_bib47","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1124\/jpet.109.157560","article-title":"Discriminative stimulus effects of 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane (DOM), ketanserin, and (R)-(+)-{\u03b1}-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-pipidinemethanol (MDL100907) in rats","volume":"331","author":"Li","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"issue":"14","key":"10.1016\/j.jpet.2025.103691_bib48","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.1007\/s00213-014-3446-0","article-title":"Mefloquine and psychotomimetics share neurotransmitter receptor and transporter interactions in vitro","volume":"231","author":"Janowsky","year":"2014","journal-title":"Psychopharmacology (Berl)"},{"issue":"3","key":"10.1016\/j.jpet.2025.103691_bib49","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S0022-3565(25)22189-9","article-title":"Lysergic acid diethylamide and 2,5-dimethoxy-4-methylamphetamine are partial agonists at serotonin receptors linked to phosphoinositide hydrolysis","volume":"246","author":"Sanders-Bush","year":"1988","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"10.1016\/j.jpet.2025.103691_bib50","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s00018-024-05519-2","article-title":"Effects of psychedelics on opioid use disorder: a scoping review of preclinical studies","volume":"82","author":"Pulido-Saavedra","year":"2025","journal-title":"Cell Mol Life Sci"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356525399040?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356525399040?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T18:56:37Z","timestamp":1761850597000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356525399040"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":49,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S0022356525399040"],"URL":"https:\/\/doi.org\/10.1016\/j.jpet.2025.103691","relation":{},"ISSN":["0022-3565"],"issn-type":[{"type":"print","value":"0022-3565"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interactions between fentanyl and 2,5-dimethoxy-4-methylamphetamine: Ventilatory effects in nonhuman primates","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpet.2025.103691","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Society for Pharmacology and Experimental Therapeutics. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103691"}}